Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Avax Techs Inc

Company price
None USD 0.00(0%)
Last update at 2026-01-29T21:04:19.757221Z
Market Cap
6.42M

Momentum Score

…

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.14M
Revenue Per Share
0.00
Gross Profit TTM
0.14M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
28.94%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Income before tax -11.99M -19.42M -6.48M -6.41M -5.36M
Minority interest 0.00M 0.00M 0.00M 0.00M -
Net income -11.99M -19.42M -6.48M -6.41M -5.36M
Selling general administrative 4.17M 2.76M 3.51M 2.71M 1.99M
Gross profit 0.14M 0.40M 0.65M 0.62M 0.73M
Ebit -5.92M -4.88M -6.07M -6.69M -5.36M
Non operating income net other 0.00M 0.00M 0.00M 0.00M -
Operating income -5.92M -4.88M -6.07M -6.69M -5.50M
Other operating expenses 0.00M 0.00M 0.00M 0.00M -
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Extraordinary items 0.00M 0.00M 0.00M 0.00M -
Non recurring 0.00M 0.00M 0.00M 0.00M -
Other items 0.00M 0.00M 0.00M 0.00M -
Income tax expense 0.00M 0.00M 0.00M 0.00M 0.00M
Total revenue 0.14M 0.40M 0.65M 0.62M 0.73M
Total operating expenses 6.06M 5.28M 6.72M 7.31M 0.00M
Cost of revenue 0.00M 0.00M 0.00M 7.37M 5.94M
Total other income expense net -6.08M -14.54M -0.42M 0.28M 0.14M
Discontinued operations 0.00M 0.00M 0.00M 0.00M -
Net income from continuing ops -11.99M -19.42M -6.48M -6.41M -5.36M
Net income applicable to common shares -11.99M -19.42M -6.48M -6.41M -5.36M
Preferred stock and other adjustments 0.00M 0.00M 0.00M 0.00M -
Breakdown 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Total assets 0.58M 1.03M 2.67M 7.38M 3.04M
Intangible assets 0.00M 0.00M 0.00M 0.20M 0.19M
Other current assets 0.22M 0.20M 0.28M 0.33M 0.21M
Total liab 21.02M 22.63M 5.29M 3.99M 2.70M
Total stockholder equity -20.44M -21.60M -2.62M 3.38M 0.34M
Deferred long term liab 0.00M 0.00M 0.00M 0.00M -
Other current liab 14.76M 16.09M 1.13M 0.25M 1.24M
Common stock 2.13M 0.57M 0.57M 0.57M 0.25M
Retained earnings -122.29M -110.29M -90.74M -84.25M -77.84M
Other liab 0.00M 0.00M 0.00M 0.00M -
Good will 0.00M 0.00M 0.00M 0.19M 0.19M
Other assets 0.12M 0.62M 1.05M 0.00M -
Cash 0.09M 0.03M 0.55M 5.90M 1.49M
Total current liabilities 21.02M 22.63M 5.29M 3.99M 2.70M
Short term debt 0.00M 0.00M 0.00M 0.00M -
Short long term debt 3.33M 1.52M 0.07M 0.42M -
Other stockholder equity 0.38M 0.33M 0.33M 0.41M 0.48M
Property plant equipment 0.08M 0.11M 0.54M 0.74M 0.88M
Total current assets 0.39M 0.30M 1.08M 6.45M 1.98M
Long term investments 0.00M 0.00M 0.00M 0.00M -
Net tangible assets -20.44M -21.60M -2.62M 3.19M 0.16M
Short term investments 0.00M 0.00M 0.00M 0.00M -
Net receivables 0.08M 0.05M 0.23M 0.21M 0.27M
Long term debt 0.00M 0.00M 0.00M 0.00M -
Inventory 0.00M 0.00M 0.01M 0.01M 0.01M
Accounts payable 2.37M 2.23M 2.00M 2.09M 1.46M
Total permanent equity 0.00M 0.00M 0.00M 0.00M -
Noncontrolling interest in consolidated entity 0.00M 0.00M 0.00M 0.00M -
Temporary equity redeemable noncontrolling interests 0.00M 0.00M 0.00M 0.00M -
Accumulated other comprehensive income 0.00M 0.00M 0.00M 0.00M -
Additional paid in capital 0.00M 0.00M 0.00M 0.00M -
Common stock total equity 0.00M 0.00M 0.00M 0.00M -
Preferred stock total equity 0.00M 0.00M 0.00M 0.00M -
Retained earnings total equity 0.00M 0.00M 0.00M 0.00M -
Treasury stock 0.00M 0.00M 0.00M 0.00M -
Accumulated amortization 0.00M 0.00M 0.00M 0.00M -
Non currrent assets other 0.00M 0.00M 0.00M 0.00M -
Deferred long term asset charges 0.00M 0.00M 0.00M 0.00M -
Non current assets total 0.00M 0.00M 0.00M 0.00M -
Capital lease obligations 0.00M 0.00M 0.00M 0.00M -
Long term debt total 0.00M 0.00M 0.00M 0.00M -
Breakdown 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Investments 0.00M 0.00M 0.00M 0.00M -
Change to liabilities -0.11M 0.59M -0.34M 1.20M 0.73M
Total cashflows from investing activities -0.00M -0.01M -0.10M -0.13M -0.04M
Net borrowings 0.23M 2.31M 1.32M 1.32M -
Total cash from financing activities 3.49M 2.31M 1.32M 9.32M 9.32M
Change to operating activities -0.22M -0.02M 0.42M -0.12M 0.16M
Net income -11.99M -19.42M -6.48M -6.41M -5.36M
Change in cash 0.06M -0.53M -5.35M 4.42M -4.09M
Total cash from operating activities -3.44M -2.85M -6.49M -4.73M -4.09M
Depreciation 0.04M 0.44M 0.29M 0.30M 0.29M
Other cashflows from investing activities 0.00M 0.00M 0.00M 0.00M -
Dividends paid 0.00M 0.00M 0.00M 0.00M -
Change to inventory 0.00M 0.01M 0.00M 0.00M 0.00M
Change to account receivables 0.00M 0.18M -0.06M 0.10M -0.12M
Sale purchase of stock 1.98M 0.88M 0.10M 9.79M 9.32M
Other cashflows from financing activities 0.00M 0.00M 0.00M 0.00M -
Change to netincome 7.19M 14.46M 0.49M 0.20M 0.15M
Capital expenditures 0.00M 0.01M 0.10M 0.13M 0.04M
Change receivables 0.00M 0.00M 0.00M 0.00M -
Cash flows other operating 0.00M 0.00M 0.00M 0.00M -
Exchange rate changes 0.00M 0.00M 0.00M 0.00M -
Cash and cash equivalents changes 0.00M 0.00M 0.00M 0.00M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Avax Techs Inc

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

2000 Hamilton Street, Philadelphia, PA, United States, 19130

215-241-9760

9

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…